Impact of Rheological Variables in Cancer

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 5, 2003, Pages 499-513

  Von Tempelhoff, Georg Friedrich ^a   Heilmann, Lothar ^a   Hommel, Gerhard ^b   Pollow, Kunhard ^b  

^a Gesundheits und Pflegezentrum Russelsheim   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anemia; Cancer prognosis; Hyperviscosity; Plasma viscosity; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; HORMONE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PACLITAXEL;

ADVANCED CANCER; ANEMIA; BLOOD FLOW VELOCITY; BLOOD RHEOLOGY; BLOOD VISCOSITY; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CORRELATION COEFFICIENT; DEEP VEIN THROMBOSIS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FIBRINOGEN METABOLISM; FLOW KINETICS; FOLLOW UP; GYNECOLOGIC CANCER; HEMATOCRIT; HEMODYNAMIC MONITORING; HUMAN; HYPERVISCOSITY SYNDROME; METASTASIS; MICROCIRCULATION; PLASMA VISCOSITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHEAR RATE; THROMBOSIS;

ANTINEOPLASTIC AGENTS; BLOOD VISCOSITY; HEMORHEOLOGY; HUMANS; NEOPLASMS; PROGNOSIS; THROMBOSIS;

EID: 0242361640     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44641     Document Type: Review

References (81)

1. Rickles FR, Levine M, Edwards RL, Moritz TE, Zacharski LR. Abnormalities of blood coagulation in patients with cancer. In: Serneri GGN, Gensini GF, Abbate R, Prisco D, eds. Thrombosis An Update. Scientific Press; 1992:241-260
2. von Tempelhoff G-F, Heilmann L. Thrombosis and hemorheology in patients with breast cancer and adjuvant chemotherapy. Clin Hemorheol 1995;15:311-323
3. Riley V. Erythrocyte sedimentation rate in breast cancer. Science 1976;191:86-88
4. Miller B, Heilmann L. Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment. Cancer 1988;62:350-354
5. Laffargue F, Brun JF, Boulet P, Elbouhmadi A, Orsetti A. Blood rheology in ovarian cancer. Clin Hemorheol 1995; 15:550 (Abst)
6. El Bouhmadi A, Laffargue F, Brun JF. Aggregability and disaggregability of erythrocytes in women suffering from ovarian cancer: evidence for an increased disaggregation threshold. Clin Hemorheol Microcirc 2000;22:91-97
7. von Tempelhoff G-F, Heilmann L, Hommel G, et al. Hyperviscosity syndrome in ovarian malignancy. Cancer 1998;82: 1104-1111
8. Miller B, Heilmann L. Hemorheological parameters in patients with gynecologic malignancies. Gynecol Oncol 1989; 33:177-181
9. Chen H, Yunpeng W, Shaoxi C, Mian LA. Research on rheological properties of erythrocyte of lung cancer patients. Clin Hemorheol 1996;16:135-141
10. Khan MM, Puniyani RR, Huilgol NG, Hussain MA, Ranade GG. Hemorheological profiles in cancer patients. Clin Hemorheol 1995;15:37-44
11. Ranade GG, Puniyana RR, Huilgol NG, Khan MM. Application of PV to assess the status of cancer patients. Clin Hemorheol 1995;15:755-761
12. Beshara S, Letocha H, Linde T, et al. Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Prostate 1997;31:153-160
13. Dintenfass L. Elevation of PV and of aggregation of red cells in melanoma metastasis. Biorheology 1978;15:99-110
14. Dintenfass L. Hemorheology of cancer metastases: an example of malignant melanoma. Survival times and abnormality of blood viscosity factors. Clin Hemorheol 1982;2:259-271
15. Humphreys WV, Walker A, Charlesworth D. Altered viscosity and yield stress in patients with abdominal malignancy: relationship to deep venous thrombosis. Br J Surg 1976;63:559-561
16. Tietjen GW, Chien S, Scholz P, Gump FE, Kinney JM. Changes in blood viscosity and plasma proteins in carcinoma. J Surg Oncol 1977;9:53-59
17. Lowe GDO. Rheological influences on thrombosis. Baillieres Clin Haematol 1994;7:573-589
18. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34
19. Dintenfass L. Hemorheology of cancer metastasis - an example of malignant melanoma, survival times and abnormality of blood viscosity factors. Clin Hemorheol 1982;2:259-271
20. von Tempelhoff G-F, Schönmann N, Pollow K, Hommel G, Heilmann L. Prognostic role of PV in breast cancer. Clin Hemorheol Microcirc Blood Flow Vessels 2002;26:55-61
21. Weiss L. The hemodynamic destruction of circulating cancer cells. Biorheology 1987;24:105-115
22. Dong C, Slattery MJ, Rank BM, You J. In vitro characterization and micromechanics of tumor cell chemotatic protrusion, locomotion, and extravasation. Ann Biomed Eng 2002;30:344-355
23. Singh A, Eckardt KU, Zimmermann A, et al. Increased PV as a reason for inappropriate erythropoietin formation. J Clin Invest 1993;91:251-256
24. Baish JW, Gazit Y, Berk DA, et al. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 1996;51:327-346
25. Chahwala SB, Hickmann JA. Effect of the antitumor drug adriamycin on human blood cell discocyte-echinocyte transitions. Cancer Res 1985;45:4986-4989
26. Vasigara-Singh W, Subramaniam S, Shyama S, JagadeEsan M, Sshyamala-Devi CS. Changes in erythrocyte membrane lipids in breast cancer patients after radiotherapy and chemotherapy. Chemotherapy 1996;42:65-70
27. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1999;78: 133-136
28. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseaus's syndrome (carcinoma induced coagulopathy) and metastasis. Cancer Res 2001;61:795-798
29. Keller DK, Nauth C, Thews O, Krueger W, Vaupel P. Localized hypothermia: impact on oxygenation, microregional perfusion, metabolic and bioenergetic status of subcutaneous rat tumours. Br J Cancer 1998;78:56-61
30. Baron JA, Cole BF, Sandler RS, et al. Randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891-899
31. Zacharski LR. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett 2002;186:1-9
32. Konerding MA, van Ackern CA, Fait E, Steinberg F, Streffer C. Morphologic aspects of tumor angiogenesis and microcirculation. In: Molls M, Vaupel P, eds. Blood Perfusion and Microenvironment of Human Tumors. Berlin: Springer-Verlag; 1998:5-18
33. Less JR, Posner MC, Boucher Y, et al. Interstitial hypertension in human tumors. Cancer Res 1992;52:6371
34. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999; 43:1111-1112
35. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-2658
36. Sevick EM, Jain RK. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res 1988;48:1201-1207
37. Lowe GDO. Blood rheology, haemostasis and vascular disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. London: Churchill Livingstone; 1994:1169-1188
38. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 1975;35:512-516
39. Funakoshi N, Onizuka M, Yanagi K, et al. A new model of lung metastasis for intravital studies. Microvasc Res 2000;59: 361-367
40. Lane DW, L'Anson S. Viscosimetric effect of fibrinogen. J Clin Pathol 1994;47:1004-1005
41. Dintenfass L, Kammer S. PV in 615 subjects. Effect of fibrinogen, globulin, and cholesterol in normals, peripheral vascular disease retinopathy, and melanoma. Biorheology 1977;14: 247-251
42. Dintenfass L. Criteria and values in diagnosis and treatment, and prevention of metastasis in neoplastic disease. In: Dintenfass L, ed. Rheology of Blood in Diagnostic and Preventive Medicine. London: Butterworths; 1976:137-162
43. von Tempelhoff G-F, Nieman F, Hommel G, Heilmann L. Association between blood rheology, thrombosis, and cancer survival in patients with gynecologic malignancy. Clin Hemorheol Microcirc Blood Flow Vessels 2000;22:107-130
44. Thompson DK, Haddow JE, Smithe DE, Ritchi RF. Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer 1983;51:2100-2104
45. Jung F, Kieseweter H, Roggenkamp HG, Nüttgens HP, Ringelstein EB. Bestimmung der Referenzbereiche rheologischer Parameter: Studie an 653 zufällig ausgewählten Probanden im Kreis Aachen. Klin Wochenschr 1986;64:375-381
46. von Tempelhoff G-F, Heilmann L. Coagulation disorders in gynecologic malignancy. In: Rath W, Heilmann L, eds. Coagulation Disorders in Obstetrics and Gynecology. New York: Thieme; 1999:66-88
47. Zacharski LR, Memoli VA, Ornstein DL, et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993;85:1225-1230
48. Moradi MM, Carson LF, Weinberg B, et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor alpha in patients with ovarian epithelial cancer. Cancer 1993;72:2433-2440
49. Semeraro N, Montemurro P, Conese M, et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies. Int J Cancer 1990;45:251-254
50. Zacharski LR, Howell AL, Memoli VA. The coagulation biology of cancer. Fibrinolysis 1992;6(suppl):39-42
51. Sorensen HT, Mellemkjaer L, Olsen J, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850
52. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 2000; 342:1953-1958
53. von Tempelhoff G-F, Heilmann L, Hommel G. Thrombosis - a clue of poor prognosis in primary non-metastatic breast cancer. Breast Cancer Res Treatment 2002;73:275-277
54. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of sodium warfarin on survival in small carcinoma of the lung. JAMA 1981;245:831-835
55. Hettiarachchi RJK, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952
56. Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. London: Churchill Livingstone; 1994:1327-1333
57. Balendra R, Rumley A, Orr M, et al. Blood lipids, coagulation, fibrinolysis and rheology in spontaneous proven deep vein thrombosis. Br J Haematol 1991;77(suppl 1):83 (Abst)
58. Chabanel A, Horellou MH, Conrad J, Samama MM. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of postthrombotic treatment. Br J Haematol 1994;88:174-179
59. Mercke CE. Anemia in patients with solid tumours and the role of erythrocyte deformability. Br J Cancer 1981;44:425-432
60. Thomas DP. Pathogenesis of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia: JB Lippincott; 1982:820-830
61. Patterson WP, Caldwell CW, Doll DC. Hyperviscosity syndromes and coagulopathies. Semin Oncol 1990;17:210-216
62. von Tempelhoff G-F, Pollow K, Schneider DM, Heilmann L. State of the art: Chemotherapy and thrombosis in gynaecological malignancy. Clin Appl Thromb Hemost 1999;5:92-104
63. Subramaniam S, Subramaniam S, Aagadeesan M, Devi SSC. Alterations in erythrocyte membrane structure of breast cancer patients treated with CMF - a lipid profile. Chemotherapy 1994;40:427-430
64. Vasigara-Singh W, Subramaniam S, Shyama S, Jagade Esan M, Shyamala-Devi CS. Changes in erythrocyte membrane lipids in breast cancer patients after radiotherapy and chemotherapy. Chemotherapy 1996;42:65-70
65. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH. The anti-neoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol 1997;99:426-432
66. Chahwala SB, Hickmann JA. Effect of the antitumor drug adriamycin on human blood cell discocyte-echinocyte transitions. Cancer Res 1985;45:4986-4989
67. Mark M, Walter R, Meredith DO, Reinhart WH. Commercial taxane formulations induce stomatocytosis and increase blood viscosity. Br J Pharmacol 2001;134:1207-1214
68. von Tempelhoff G-F, Heilmann L. Thrombosis and hemorheology in patients with breast cancer and adjuvant chemotherapy. Clin Hemorheol 1995;15:311-323
69. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J. Changes of blood viscosity in patients treated with 5-fluorouracil - a link to cardiotoxicity? Acta Oncol 1995;34:83-85
70. von Tempelhoff G-F, Niemann F, Schneider D, et al. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998;90:73-82
71. Rapp S. Hemorheology in Cervical and Endometrial Cancer Patients. Mainz, Germany: Johannes Gutenberg Universität Mainz; 2001. Inaugural dissertation
72. Höckel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515
73. Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: elevation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316-3322
74. Vaupel P, Briest S, Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 2002;152:334-342
75. von Tempelhoff G-F, Hommel G, Heilmann L Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma induced coagulopathy) and metastasis. Cancer Res 2001;61:7697-7698
76. Akhtar N, Thompson J, Durrant ST, et al. The clinical relevance of plasma viscosity in Hodgkin's disease. Clin Lab Haematol 1991;13:1-8
77. Koenig W, Sund M, Lowel H, Doring A, Ernst E. Association between PV and all-cause mortality results from the MONICA-Augsburg Cohort Study 1984-92. Br J Haematol 2000;109:453-458
78. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, eds. Blood Perfusion and Microenvironment of Human Tumors. Berlin: Springer-Verlag; 1998:101-112
79. Obermair A, Handisurya A, Kaider A, et al. The relation of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 1998;83:726-731
80. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsburg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277
81. Vaupel P, Menke H. Blood flow, vascular resistance and oxygen availability in malignant tumors upon intravenous flunaritine. Adv Exp Med Biol 1987;215:393-398 513